Retraction: Late complications of clinical Clostridium histolyticum collagenase use in Dupuytren's disease.

Retraction: Late complications of clinical Clostridium histolyticum collagenase use in Dupuytren's disease.

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3490484

Similar Items

Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.
by: Warren M Rozen, et al.
Published: (2012-01-01)

Efficacy of Collagenase Clostridium Histolyticum for Dupuytren Disease: A Systematic Review
by: Rafael Sanjuan-Cerveró, et al.
Published: (2017-11-01)

Multiple concurrent collagenase clostridium histolyticum injections to dupuytren’s cords: an exploratory study
by: Coleman Stephen, et al.
Published: (2012-04-01)

Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation
by: Miriam Brazzelli, et al.
Published: (2015-10-01)

Clostridium Histolyticum Collagenase Underdosed for Multicord Injection in Dupuytren’s Disease: A Retrospective Cohort Study
by: Filippo Boriani, MD, MSc, PhD, et al.
Published: (2022-11-01)

Acute Pain Intensity After Collagenase Clostridium histolyticum Injection in Patients With Dupuytren Contracture
by: Kimitoshi Noto, MD, et al.
Published: (2020-01-01)

Treatment of Dupuytren’s contracture with collagenase clostridium histolyticum under clinical practice conditions: ReDUCTo study
by: Haerle, Max, et al.
Published: (2015-08-01)

The efficacies and limitations of fasciectomy and collagenase clostridium histolyticum in Dupuytren’s contracture management: A meta-analysis
by: Tokai B Cooper, et al.
Published: (2020-06-01)

Magnetic resonance imaging of diffusion characteristics following collagenase clostridium histolyticum injection in Dupuytren’s contracture
by: Hiroko Iwakawa, et al.
Published: (2021-09-01)

Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis
by: Zah V, et al.
Published: (2020-11-01)

[Translated article] Colagenasa Clostridium histolyticum for Dupuytren's disease: A shooting star
by: R. Sanjuan-Cerveró
Published: (2022-05-01)

Cost per Episode of Care With Collagenase Clostridium histolyticum Versus Fasciectomy for Dupuytren Contracture: A Real-World Claims Database Analysis
by: Stephen B. Camper, MS, PhD, et al.
Published: (2019-04-01)

Collagenase Clostridium histolyticum in the treatment of Peyronie’s disease: patient selection and perspectives
by: Kuhlmann PK, et al.
Published: (2017-03-01)

Lateral herniation during treatment with collagenase Clostridium histolyticum (Xiaflex) for Peyronie’s disease
by: Margaret K. Gannon, et al.
Published: (2021-06-01)

The Impact of Clostridium Histolyticum Collagenase on the Prevalence and Management of Peyronie’s Disease in the United States
by: Andrew J. Sun, et al.
Published: (2019-05-01)

Tolerability and Safety of Collagenase Clostridium Histolyticum Injection in Participants with Plantar Fibromatosis
by: Richard Pollak DPM, MS, et al.
Published: (2023-12-01)

Monitoring the Degradation of Collagen Hydrogels by Collagenase <i>Clostridium histolyticum</i>
by: Hon Wei Ng, et al.
Published: (2020-11-01)

Improvement in the ability to have sex in patients with Peyronie's disease treated with Collagenase Clostridium histolyticum
by: Jeannette P. Geelhoed, et al.
Published: (2023-01-01)

Efficacy of Collagenase Clostridium Histolyticum (CCH, Xiapex®) in patients with acute phase of Peyronie’s disease
by: A. Cocci, et al.
Published: (2020-07-01)

Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects
by: María Alejandra Egui Rojo, et al.
Published: (2014-10-01)

Colagenasa Clostridium histolyticum para la enfermedad de Dupuytren: una estrella fugaz
by: R. Sanjuan-Cerveró
Published: (2022-05-01)

Safety and Efficacy Study of Collagenase Clostridium Histolyticum Applied With an Intensive Protocol in the Treatment of Peyronie's Disease
by: Mª Teresa Melgarejo-Segura, et al.
Published: (2021-06-01)

Re: Collagenase Clostridium Histolyticum for the Treatment of Peyronie’s Disease: A Prospective Italian Multicentric Study
by: Emre Bakırcıoğlu
Published: (2019-03-01)

Collagenase Clostridium Histolyticum in the Treatment of Peyronie’s Disease: Review of a Minimally Invasive Treatment Option
by: Andrew T Gabrielson, et al.
Published: (2017-12-01)

Surgical outcomes after collagenase Clostridium histolyticum failure in patients with Peyronie’s disease in a multicenter clinical study
by: Andrea Cocci, et al.
Published: (2021-01-01)

The effect of collagenase clostridium histolyticum on adhesion reduction in a rat knee arthrofibrosis model
by: Nazım Karahan, et al.
Published: (2021-09-01)

Optimization of Col H Gene Encoding Clostridium histolyticum Collagenase to Express in Escherichia coli
by: Seyed Mohammad Amin Mahdian, et al.
Published: (2022-01-01)

Editorial Comment: Risk Factors for Penile Fracture After Intralesional Collagenase Clostridium histolyticum in Peyronie's Disease
by: Luciano A. Favorito
Published: (2024-04-01)

Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners
by: Irwin Goldstein, MD, et al.
Published: (2017-06-01)

How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie’s Disease Receiving Collagenase Clostridium Histolyticum Therapy?
by: Andrea Cocci, et al.
Published: (2020-01-01)

Delayed vascular complication after collagenase injection for Dupuytren disease
by: Jesper Nordenskjöld, et al.
Published: (2023-10-01)

Characterization of Tissue Histology for the Injectable Cellulite Treatment Collagenase Clostridium Histolyticum-aaes: Results in Swine
by: Sachin M Shridharani, et al.
Published: (2023-04-01)

Can You Go the Distance: Collagenase Clostridium histolyticum Manipulation at 1 Month after Injection
by: Lacey R. Pflibsen, MD, et al.
Published: (2023-09-01)

Collagenase <i>Clostridium histolyticum</i> for the Treatment of Cellulite in the Buttocks and Thigh: Early Insights From Clinical Practice
by: Miles Graivier, et al.
Published: (2022-06-01)

Post-infiltration ultrasound evaluation of collagenase clostridium histolyticum for the treatment of Peyronie’s disease: Independent factor of therapeutic success
by: A. Cocci, et al.
Published: (2020-07-01)

Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials
by: Lawrence S. Bass, MD, et al.
Published: (2022-05-01)

Editorial Comment: Impact of the advent of collagenase clostridium histolyticum on the surgical management of Peyronie's disease: a population-based analysis
by: S Sukumar, et al.
Published: (2020-03-01)

The efficacy and safety of intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease: A meta-analysis of published prospective studies
by: Fuxun Zhang, et al.
Published: (2022-10-01)

Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciectomy in the treatment of Dupuytren’s contracture: a network meta-analysis of randomized controlled trials
by: Doha Obed, et al.
Published: (2022-10-01)

Real-World Experience With Collagenase Clostridium Histolyticum-aaes for Buttock and Thigh Cellulite: Focus on Administration and Safety Profile
by: Sachin M Shridharani, et al.
Published: (2023-02-01)